Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending July 18, 2016. The document serves as a transaction notification regarding a Person Discharging Managerial Responsibilities (PDMR) rather than a comprehensive financial report.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The only financial data present relates to a specific share transaction:
- Transaction Price: £16.6781 per share
- Transaction Volume: 1,560.894 Ordinary Shares
- Instrument: Ordinary shares of 25 pence each (ISIN: GB0009252882)
Material Changes
No material changes to the company's financial position or operations are reported in this document. The filing details a single acquisition of shares by Dr. P J T Vallance (President, Pharmaceuticals R&D) on July 14, 2016, executed on the London Stock Exchange. This acquisition resulted from the re-investment of dividends paid to shareholders.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is strictly a regulatory notification of an insider transaction.
Investor Verification Points
- Verify the dividend reinvestment plan terms applicable to July 14, 2016.
- Confirm the total shareholding of Dr. P J T Vallance following this transaction.
- Review the company's full financial results for the period in separate filings (e.g., Form 20-F or interim reports) as this 6-K contains no aggregate financial data.